Meta‐analysis of Association between Newer Glucose‐Lowering Drugs and Risk of Parkinson's Disease

Tang, Huilin; Lu, Ying; Okun, Michael S.; Donahoo, William T.; Ramirez‐Zamora, Adolfo; Wang, Fei; Huang, Yu; Chen, Wei‐Han; Virnig, Beth A.; Bian, Jiang; Guo, Jingchuan

doi:10.1002/mdc3.13893

Cited by 4 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seizures and other neurological deficits may also present during hypoglycemia (Barbara et al., 2017 ). In contrast to the current research findings, some studies indicate that SGLT2i may provide neuroprotective effects by improving mitochondrial function and antioxidative effects, potentially benefiting the control of PD progression (Lin et al., 2021 ; Tang et al., 2023 ).…”

Section: Discussionmentioning

confidence: 99%

Sodium‐glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study

Liu,

Shi,

Shao

2024

Brain and Behavior

View full text Add to dashboard Cite

IntroductionThis study aims to evaluate the effects of sodium‐glucose cotransporter 1 inhibitors (SGLT1i) and sodium‐glucose cotransporter 2 inhibitors (SGLT2i) on neurodegenerative disorders and to investigate the role of hemoglobin A1c (HbA1c) levels.MethodsUtilizing drug target Mendelian randomization, we employed single nucleotide polymorphisms (SNPs) proximal to the SLC5A1 and SLC5A2 genes to analyze the influence of SGLT1i and SGLT2i on Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), frontotemporal dementia (FTD), Lewy body dementia (LBD), and amyotrophic lateral sclerosis (ALS), with type 2 diabetes (T2D) as a positive control. An additional analysis examined the impact of HbA1c levels on the same disorders.ResultsSGLT1i exhibited a significant association with decreased risk for ALS and MS. Conversely, SGLT2i were linked to an increased risk of AD, PD, and MS. Elevated HbA1c levels, independent of SGLT1 and SGLT2 effects, were associated with an increased risk of PD. Sensitivity analyses supported the robustness of these findings.ConclusionOur study suggests that SGLT1i may confer protection against ALS and MS, whereas SGLT2i could elevate the risk of AD, PD, and MS. Additionally, elevated HbA1c levels emerged as a risk factor for PD. These findings underscore the importance of personalized approaches in the utilization of SGLT inhibitors, considering their varying impacts on the risks of neurodegenerative diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Sodium‐glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study

Liu,

Shi,

Shao

2024

Brain and Behavior

View full text Add to dashboard Cite

show abstract

“…Identifying risk factors and potential causes of Parkinson's disease might assist in developing treatments for the disease. For example, it is possible that glucose-lowering drugs used to control symptoms of type II diabetes might reduce the risk of developing Parkinson's disease [85].…”

Section: Potential Causesmentioning

confidence: 99%

Parkinson’s Disease and Photobiomodulation: Potential for Treatment

Bicknell,

Liebert,

Herkes

2024

JPM

View full text Add to dashboard Cite

Parkinson’s disease is the second most common neurodegenerative disease and is increasing in incidence. The combination of motor and non-motor symptoms makes this a devastating disease for people with Parkinson’s disease and their care givers. Parkinson’s disease is characterised by mitochondrial dysfunction and neuronal death in the substantia nigra, a reduction in dopamine, accumulation of α-synuclein aggregates and neuroinflammation. The microbiome–gut–brain axis is also important in Parkinson’s disease, involved in the spread of inflammation and aggregated α-synuclein. The mainstay of Parkinson’s disease treatment is dopamine replacement therapy, which can reduce some of the motor signs. There is a need for additional treatment options to supplement available medications. Photobiomodulation (PBM) is a form of light therapy that has been shown to have multiple clinical benefits due to its enhancement of the mitochondrial electron transport chain and the subsequent increase in mitochondrial membrane potential and ATP production. PBM also modulates cellular signalling and has been shown to reduce inflammation. Clinically, PBM has been used for decades to improve wound healing, treat pain, reduce swelling and heal deep tissues. Pre-clinical experiments have indicated that PBM has the potential to improve the clinical signs of Parkinson’s disease and to provide neuroprotection. This effect is seen whether the PBM is directed to the head of the animal or to other parts of the body (remotely). A small number of clinical trials has given weight to the possibility that using PBM can improve both motor and non-motor clinical signs and symptoms of Parkinson’s disease and may potentially slow its progression.

show abstract

Newer glucose‐lowering drugs and risk of suicidal ideation and behaviours: A network meta‐analysis of randomized outcome trials

Lu,

Tang,

Kotecha

et al. 2024

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Meta‐analysis of Association between Newer Glucose‐Lowering Drugs and Risk of Parkinson's Disease

Cited by 4 publications

References 41 publications

Sodium‐glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study

Sodium‐glucose cotransporter 1/2 inhibition and risk of neurodegenerative disorders: A Mendelian randomization study

Parkinson’s Disease and Photobiomodulation: Potential for Treatment

Newer glucose‐lowering drugs and risk of suicidal ideation and behaviours: A network meta‐analysis of randomized outcome trials

Contact Info

Product

Resources

About